Second generation CAR-T cells

GENETIC2 trials

Sponsors

Wuhan Sian Medical Technology Co., Ltd

Conditions

Acute Lymphoblastic LeukemiaB Cell Lymphoma

Phase 1

CD19 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With B-cell Malignancies

Wuhan Sian Medical Technology Co., LtdAcute Lymphoblastic Leukemia, B Cell Lymphoma

Start: 2015-12-02End: 2021-12-31Target: 80Updated: 2019-05-10

Anti-CD19 CAR-T Therapy Combine With HSCT to Treat MRD+ B-cell Malignancies

Wuhan Sian Medical Technology Co., LtdAcute Lymphoblastic Leukemia, B Cell Lymphoma

Start: 2016-05-01End: 2021-06-01Target: 20Updated: 2018-11-20

Related Papers

The impact of obesity and its related underlying diseases on cytokine release syndrome and the efficacy of CAR-T therapy in treating B-cell malignancies

Annals of Hematology2025-03-012 citations

Timing of Tocilizumab Administration Under the Guidance of IL-6 in CAR-T Therapy for R/R Acute Lymphoblastic Leukemia

Frontiers in Immunology2022-06-2123 citations

Single-Cell Analyses Identify Transcriptional Characterizations of Subsets Associated with Efficacy and Toxicity for CAR-T Immunotherapy in B-ALL Patients

Blood2021-11-051 citations

Timing of Tocilizumab and Corticosteroids Administration Under the Guidance of IL-6 in CAR-T Therapy for R/R Acute Lymphoblastic Leukemia

Blood2021-11-05

PS941 ANTI‐CD19 CAR‐T THERAPY BRIDGING TO ALLO‐HSCT IMPROVES LONG‐TERM OUTCOME OF B‐ALL PATIENTS WITH HIGH LEUKEMIA BURDEN OR POOR PROGNOSTIC MARKERS

HemaSphere2019-06-01

PS1222 IL‐6 ASSOCIATED WITH GRADING OF CYTOKINE RELEASE SYNDROME AND MANAGEMENT TIME OF TOCILIZUMAB AFTER CAR‐T CELL THERAPY

HemaSphere2019-06-01

Improving the safety of CAR-T cell therapy by controlling CRS-related coagulopathy.

2019-05-0491 citations

Abnormal Coagulation Function in CD19-Targeted CAR-T Therapy

Blood2017-12-071 citations